Business Context and Reporting Period
Company: Schering-Plough Corporation (Note: Input metadata referenced Merck & Co., Inc., but the filing text is for Schering-Plough).
Reporting Period: Fiscal year ended December 31, 2003.
Overview: Schering-Plough is a global pharmaceutical company operating in Prescription Pharmaceuticals, Consumer Health Care, and Animal Health segments. The 2003 fiscal year was characterized by a severe decline in earnings and cash flow driven by the loss of marketing exclusivity for its leading product, CLARITIN, following its switch to over-the-counter (OTC) status in December 2002. Additionally, the company faced intense competition in the hepatitis C market for its INTRON franchise and significant regulatory challenges, including an FDA consent decree regarding manufacturing practices and multiple federal investigations into marketing practices.
Key Financial Metrics
| Metric | 2003 | 2002 | Change |
|---|---|---|---|
| Net Sales | $8,334 million | $10,180 million | (18)% |
| Net (Loss)/Income | ($92) million | $1,974 million | Turned to Loss |
| Diluted EPS | ($0.06) | $1.34 | N/A |
| Operating Cash Flow | $601 million | $1,980 million | (70)% |
| Long-Term Debt | $2,410 million | $21 million | Significant Increase |
| Cash & Equivalents | $4,218 million | $3,521 million | 19.8% |
| Research & Development | $1,469 million | $1,425 million | 3% |
Margins: Cost of sales as a percentage of net sales increased to 34.0% in 2003 from 24.6% in 2002. Selling, general, and administrative expenses rose to 41.7% of sales from 36.2%.
Liquidity: While total cash and short-term investments exceeded total debt by $1.4 billion, approximately 86% of cash was held by foreign subsidiaries, while debt was primarily held by U.S. entities. The company reduced its quarterly dividend from 17 cents to 5.5 cents per share.
Material Changes vs. Prior Period
- Revenue Decline: Consolidated net sales dropped 18% to $8.3 billion. U.S. sales fell 38%, while international sales grew 8%.
- Product Performance:
- CLARITIN: U.S. prescription sales collapsed from $1.4 billion in 2002 to $25 million in 2003 following the OTC switch.
- INTRON Franchise: Sales declined 32% to $1.9 billion due to new competition in the hepatitis C market.
- OTC CLARITIN: Generated $415 million in sales in 2003, partially offsetting prescription losses but facing generic competition.
- Special Charges: The company recorded $599 million in special charges in 2003, compared to $150 million in 2002. This included $350 million for litigation reserves, $179 million for employee termination costs (Voluntary Early Retirement Program), and $70 million in asset impairments.
- Debt Structure: Long-term debt surged from $21 million to $2.4 billion, primarily due to the issuance of $2.4 billion in senior unsecured notes in November 2003 to fund operations and repay commercial paper.
Guidance, Outlook, and Risks
Outlook: Management expects 2004 year-over-year comparisons to be negatively impacted by continued sales declines in key franchises and the absence of LOSEC revenues. Recovery is heavily dependent on the success of the cholesterol joint venture with Merck & Co., Inc. (ZETIA), which generated $471 million in global sales in 2003. Management believes financial strength may not be rebuilt until 2005 if the joint venture is highly successful.
Cost Cutting: The "Value Enhancement Initiative" (VEI) targets a 10% reduction in payroll and related expenses. Approximately 900 employees retired under a Voluntary Early Retirement Program.
Material Risks and Contingencies:
- Legal Investigations: The company is a target of federal criminal investigations (Boston Target Letter) regarding anti-kickback statutes, off-label promotion, and Medicaid rebate calculations. Litigation reserves were increased by $350 million in 2003, but final settlements could materially exceed accrued amounts.
- FDA Consent Decree: Ongoing obligations to revalidate manufacturing processes in New Jersey and Puerto Rico. Failure to meet deadlines could result in fines up to $175 million and production halts.
- Patent Litigation: Loss of patent protection for CLARITIN and potential generic entry for REBETOL in 2004.
- Credit Ratings: Credit ratings were downgraded by S&P, Moody's, and Fitch in late 2003 and early 2004 due to earnings weakness and cash flow declines.
Investor Verification Checklist
- Litigation Exposure: Verify the sufficiency of the $350 million litigation reserve against potential fines from federal investigations into marketing practices and Medicaid rebates.
- Manufacturing Compliance: Monitor progress on FDA consent decree revalidation milestones to assess risk of production stoppages or additional penalties.
- ZETIA Performance: Track sales growth and market share of the ZETIA joint venture with Merck as the primary driver for future recovery.
- Liquidity Constraints: Assess the ability to repatriate foreign cash to service U.S. debt without incurring significant U.S. income taxes, given the geographic mismatch of assets and liabilities.
- Generic Competition: Evaluate the impact of anticipated generic entry for REBETOL in 2004 on the INTRON franchise revenue.